Basic and clinical studies on sparfloxacin in the urological field

Satoshi Uno, Yoshio Nishitani, Daisuke Yamada, Masaya Tsugawa, Hiromi Kumon, Hiroyuki Ohmori, Katsuichi Nanba, Mikio Kishi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We studied the antibacterial activity and clinical efficacy of sparfloxacin, a new quinolone, in the urological field. 1) Antibacterial activity: We determined the MICs of sparfloxacin against clinical isolates (209 strains of 14 species) from urinary tract infections, and compared them with those of norfloxacin (NFLX), ofloxacin (OFLX), enoxacin (ENX) and ciprofloxacin (CPFX). The overall antibacterial activities of sparfloxacin were slightly inferior to CPFX but still excellent and superior to those of other control drugs. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 100% (3/3) for acute uncomplicated cystitis and 57.9% (11/19) for chronic complicated UTI. Baeteriologically, 18 of 25 strains (72.0%) were eradicated. 3) Side effects: Diarrhea was noted in one patient, but it improved without therapy. No abnormal laboratory findings were noted.

Original languageEnglish
Pages (from-to)513-522
Number of pages10
JournalChemotherapy
Volume39
DOIs
Publication statusPublished - 1991

Fingerprint

Ciprofloxacin
Enoxacin
Norfloxacin
Ofloxacin
Cystitis
Drug and Narcotic Control
Quinolones
Urinary Tract Infections
Diarrhea
sparfloxacin
Clinical Studies
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Basic and clinical studies on sparfloxacin in the urological field. / Uno, Satoshi; Nishitani, Yoshio; Yamada, Daisuke; Tsugawa, Masaya; Kumon, Hiromi; Ohmori, Hiroyuki; Nanba, Katsuichi; Kishi, Mikio.

In: Chemotherapy, Vol. 39, 1991, p. 513-522.

Research output: Contribution to journalArticle

Uno, S, Nishitani, Y, Yamada, D, Tsugawa, M, Kumon, H, Ohmori, H, Nanba, K & Kishi, M 1991, 'Basic and clinical studies on sparfloxacin in the urological field', Chemotherapy, vol. 39, pp. 513-522. https://doi.org/10.11250/chemotherapy1953.39.Supplement4_513
Uno, Satoshi ; Nishitani, Yoshio ; Yamada, Daisuke ; Tsugawa, Masaya ; Kumon, Hiromi ; Ohmori, Hiroyuki ; Nanba, Katsuichi ; Kishi, Mikio. / Basic and clinical studies on sparfloxacin in the urological field. In: Chemotherapy. 1991 ; Vol. 39. pp. 513-522.
@article{8168adbc23824a228018f48af4d8ef5e,
title = "Basic and clinical studies on sparfloxacin in the urological field",
abstract = "We studied the antibacterial activity and clinical efficacy of sparfloxacin, a new quinolone, in the urological field. 1) Antibacterial activity: We determined the MICs of sparfloxacin against clinical isolates (209 strains of 14 species) from urinary tract infections, and compared them with those of norfloxacin (NFLX), ofloxacin (OFLX), enoxacin (ENX) and ciprofloxacin (CPFX). The overall antibacterial activities of sparfloxacin were slightly inferior to CPFX but still excellent and superior to those of other control drugs. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 100{\%} (3/3) for acute uncomplicated cystitis and 57.9{\%} (11/19) for chronic complicated UTI. Baeteriologically, 18 of 25 strains (72.0{\%}) were eradicated. 3) Side effects: Diarrhea was noted in one patient, but it improved without therapy. No abnormal laboratory findings were noted.",
author = "Satoshi Uno and Yoshio Nishitani and Daisuke Yamada and Masaya Tsugawa and Hiromi Kumon and Hiroyuki Ohmori and Katsuichi Nanba and Mikio Kishi",
year = "1991",
doi = "10.11250/chemotherapy1953.39.Supplement4_513",
language = "English",
volume = "39",
pages = "513--522",
journal = "Chemotherapy",
issn = "0009-3165",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Basic and clinical studies on sparfloxacin in the urological field

AU - Uno, Satoshi

AU - Nishitani, Yoshio

AU - Yamada, Daisuke

AU - Tsugawa, Masaya

AU - Kumon, Hiromi

AU - Ohmori, Hiroyuki

AU - Nanba, Katsuichi

AU - Kishi, Mikio

PY - 1991

Y1 - 1991

N2 - We studied the antibacterial activity and clinical efficacy of sparfloxacin, a new quinolone, in the urological field. 1) Antibacterial activity: We determined the MICs of sparfloxacin against clinical isolates (209 strains of 14 species) from urinary tract infections, and compared them with those of norfloxacin (NFLX), ofloxacin (OFLX), enoxacin (ENX) and ciprofloxacin (CPFX). The overall antibacterial activities of sparfloxacin were slightly inferior to CPFX but still excellent and superior to those of other control drugs. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 100% (3/3) for acute uncomplicated cystitis and 57.9% (11/19) for chronic complicated UTI. Baeteriologically, 18 of 25 strains (72.0%) were eradicated. 3) Side effects: Diarrhea was noted in one patient, but it improved without therapy. No abnormal laboratory findings were noted.

AB - We studied the antibacterial activity and clinical efficacy of sparfloxacin, a new quinolone, in the urological field. 1) Antibacterial activity: We determined the MICs of sparfloxacin against clinical isolates (209 strains of 14 species) from urinary tract infections, and compared them with those of norfloxacin (NFLX), ofloxacin (OFLX), enoxacin (ENX) and ciprofloxacin (CPFX). The overall antibacterial activities of sparfloxacin were slightly inferior to CPFX but still excellent and superior to those of other control drugs. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 100% (3/3) for acute uncomplicated cystitis and 57.9% (11/19) for chronic complicated UTI. Baeteriologically, 18 of 25 strains (72.0%) were eradicated. 3) Side effects: Diarrhea was noted in one patient, but it improved without therapy. No abnormal laboratory findings were noted.

UR - http://www.scopus.com/inward/record.url?scp=0025859747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025859747&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.39.Supplement4_513

DO - 10.11250/chemotherapy1953.39.Supplement4_513

M3 - Article

AN - SCOPUS:0025859747

VL - 39

SP - 513

EP - 522

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

ER -